Back to top
more

Prothena (PRTA)

(Delayed Data from NSDQ)

$9.42 USD

9.42
363,633

+0.03 (0.32%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $9.42 0.00 (0.00%) 4:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View

by Zacks Equity Research

Celgene (CELG) reports better-than-expected results for the second-quarter, on the back of growth in Revlimid sales. The company also raises its annual guidance.

    Zacks Equity Research

    Prothena (PRTA) Down 3.5% Since Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Zacks Equity Research

      Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst

      by Zacks Equity Research

      Biotech major Celgene presents encouraging data on its oncology drugs Revlimid, Pomalyst along with other experimental therapies at the ASCO.

        Zacks Equity Research

        Implied Volatility Surging for Prothena (PRTA) Stock Options

        by Zacks Equity Research

        Prothena (PRTA) needs investors to pay close attention to the stock based on moves in the options market lately.

          Zacks Equity Research

          Prothena Restructures Resources, to Cut Workforce by 57%

          by Zacks Equity Research

          Prothena announces a reduction in workforce by 57%, due to the discontinuation of lead program, NEOD001.

            Zacks Equity Research

            Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss

            by Zacks Equity Research

            Prothena's (PRTA) wider-than-expected loss in the first quarter was disappointing. Sales also missed estimates by a huge margin.

              Zacks Equity Research

              Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength

              by Zacks Equity Research

              Celgene (CELG) surpasses both earnings and sales estimates in the first quarter on the back of impressive performance from Pomalyst and Otezla.

                Zacks Equity Research

                What's in Store for Prothena (PRTA) This Earnings Season?

                by Zacks Equity Research

                Prothena (PRTA) has faced quite a few setbacks in the year so far and hence investors will be focused on management's strategy when it reports first-quarter results next week.

                  Zacks Equity Research

                  Implied Volatility Surging for Prothena (PRTA) Stock Options

                  by Zacks Equity Research

                  Prothena (PRTA) needs investors to pay close attention to the stock based on moves in the options market lately.

                    Zacks Equity Research

                    Acorda Files Parkinson's Drug Marketing Application in EU

                    by Zacks Equity Research

                    Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.